Roche has announced results from the TSIX Study Program, validating its new sixth-generation high-sensitivity Troponin T test (Elecsys® Troponin T hs Gen 6) for rapid heart attack diagnosis. The test, recently granted CE Mark approval, delivers higher sensitivity and accuracy, enabling faster and more reliable emergency triage.
Over 13,000 participants from the U.S., EU, China, and Japan were included in the TSIX global study — the largest of its kind for troponin testing. With chest pain being among the top three emergency complaints but only 10% due to heart attack, rapid and precise diagnostics are essential for resource prioritization.
Roche’s CEO, Matt Sause, emphasized the test’s ability to detect even minimal troponin elevations, ensuring timely treatment “when every second counts.”Building on a 30-year legacy in troponin innovation, Roche plans further launches integrating digital algorithms, biomarkers, and near-patient devices for coronary care.
Overall, the new assay sets a global benchmark for standardized, high-sensitivity cardiac diagnostics, advancing early detection and optimized emergency care worldwide.
